The two direct-acting antiviral (2D) regimen of ombitasvir and paritaprevir (administered with low-dose ritonavir) is being developed for treatment of genotype subtype 1b and genotypes 2 and 4 chronic hepatitis C virus (HCV) infection. Drug-drug interactions were evaluated in healthy volunteers to develop dosing recommendations for HCV-infected subjects. Mechanism-based interactions were evaluated for ketoconazole, pravastatin, rosuvastatin, digoxin, warfarin, and omeprazole. Interactions were also evaluated for duloxetine, escitalopram, methadone, and buprenorphine-naloxone. Ratios of geometric means with 90% confidence intervals for the maximum plasma concentration and the area under the plasma concentration-time curve were estimated to assess the magnitude of the interactions. For most medications, coadministration with the 2D regimen resulted in a <50% change in exposures. Ketoconazole, digoxin, pravastatin, and rosuvastatin exposures increased by up to 105%, 58%, 76%, and 161%, respectively, and omeprazole exposures decreased by approximately 50%. Clinically meaningful changes in ombitasvir, paritaprevir, or ritonavir exposures were not observed. In summary, all 11 medications evaluated can be coadministered with the 2D regimen, with most medications requiring no dose adjustment. Ketoconazole, digoxin, pravastatin, and rosuvastatin require lower doses, and omeprazole may require a higher dose. No dose adjustment is required for the 2D regimen.
TABLE 1 Medications evaluated in the drug-drug interaction studies with the 2D regimen of ombitasvir and paritaprevir-ritonavir

| Drug class       | No. of subjects | Medication (dose)       | Mechanism                                                                 | Drug interactions with commonly used medications |
|------------------|-----------------|-------------------------|---------------------------------------------------------------------------|-----------------------------------------------|
| Antifungals      | 12              | Ketoconazole (400 mg once daily) | Effect of CYP3A and P-gp inhibition by ketoconazole on the 2D regimen | 12 Methadone (CYP3A4/CYP2B6 substrate) |
|                  |                 | Warfarin (5 mg)         | Effect of CYP2C9 inhibition/induction by the 2D regimen on warfarin        | (individualized once-daily dosing 20–120 mg per physician’s prescription) |
|                  | 12              | Omeprazole (40 mg once daily) | Effect of CYP2C19 inhibition/induction by the 2D regimen on omeprazole    | 11 Buprenorphine (CYP3A4; UGT1A1* substrate) |
|                  |                 | Digoxin (0.5 mg)        | Effect of P-gp inhibition by the 2D regimen on digoxin                    | (individualized once-daily dosing 4–24 mg per physician’s prescription) |
|                  | 12              | Pravastatin (10 mg once daily) | Effect of OATP1B1/B3 inhibition by the 2D regimen on pravastatin         | Naloxone (UGT substrate) (individualized once-daily dosing 1–6 mg per physician’s prescription) |
|                  | 12              | Rosuvastatin (3 mg once daily) | Effect of OATP1B1/B3 + BCRP inhibition by the 2D regimen on rosuvastatin | 12 Esculopram (CYP3A4/CYP2C19 substrate) (10 mg) |
|                  | 12              | Duloxetine (CYP2D6/CYP1A2 substrate and CYP1A2 inhibitor) (60 mg) |                                                      | 12 Duloxetine (CYP2D6/CYP1A2 substrate and CYP1A2 inhibitor) (60 mg) |
| Antiarrhythmics   |                 |                         |                                                                           |                                               |
| Statins          | 12              | Rosuvastatin (3 mg once daily) | Effect of OATP1B1/B3 + BCRP inhibition by the 2D regimen on rosuvastatin |                                               |

Note: UGT1A1, UDP glucuronosyltransferase 1A1.

MATERIALS AND METHODS

Study designs. Eight open-label, phase 1 clinical studies were conducted in healthy volunteers in accordance with good clinical practice guidelines and ethical principles that have their origin in the Declaration of Helsinki. The studies were performed among 4 clinical study sites in the United States and Canada between July 2012 and September 2013. The study protocols and amendments were approved by the institutional review boards, and written informed consent was obtained from each subject before any study-related procedures were performed. These studies included multiple treatment arms, and the results from the arms that received the three-DAA (3D) regimen of ombitasvir, paritaprevir-ritonavir, and dasabuvir have been reported previously (18). The results from the treatment arms that received the 2D regimen are the primary focus of this report.

Inhibitors of metabolic enzymes and drug transporters were not allowed within 1 month of enrollment. The subjects enrolled in the methadone and buprenorphine-naloxone studies had been taking stable doses of methadone or buprenorphine-naloxone for a minimum of 14 days before the screening visit. Subjects with clinically significant renal disease were excluded from participation in all studies.

The drug-drug interactions were evaluated for the 2D regimen of ombitasvir (25 mg) and paritaprevir-ritonavir (150/100 mg) using 11 medications from several different drug classes (Table 1). The key aspects of the study designs are presented in Fig. 1. Most evaluations were conducted under once-daily, multiple-dosing conditions, although a few mechanism-based interactions were evaluated under single-dosing conditions. For all evaluations, ombitasvir and paritaprevir-ritonavir were coadministered with the interacting medications after consumption of a moderate-fat meal (approximately 1,900 to 2,300 cal/day with 40% of calories from fat).

Safety and tolerability. The safety and tolerability of the 2D regimen and the interacting medications were assessed based on adverse event monitoring, physical examinations, laboratory tests, vital signs, and electrocardiogram assessments.

Pharmacokinetic evaluations. Intensive pharmacokinetic sampling was performed as noted in Fig. 1 for determination of the plasma concentrations of paritaprevir, ritonavir, ombitasvir, and the interacting medications and their metabolites, if applicable. The plasma concentrations were determined using validated liquid chromatography with tandem mass spectrometric detection methods. The lower limits of quantitation (LLOQs) for paritaprevir, ritonavir, and ombitasvir were 0.6 ng/ml [intraday accuracy (percent bias), −1.0% to 4.5%; intraday precision (percent coefficient of variation [%CV]), 5.00% to 7.00%], 4.9 ng/ml [percent bias, −4.3% to −0.1%; %CV, 2.8% to 4.2%], and 0.5 ng/ml (percent bias, 0.7% to 4.7%; %CV, 3.8% to 5.3%), respectively. The LLOQs for the concomitant medications were 0.01 ng/ml for digoxin (percent bias, −3.99% to 2.05%; %CV, 3.71% to 9.64%), 0.02 ng/ml for naloxone (percent bias, −2.8% to −0.9%; %CV, 1.9% to 3.5%), 0.05 ng/ml for S-desmethylcitalopram (percent bias, −5.01% to 3.24%; %CV, 2.97% to 11.71%), 0.1 ng/ml for buprenorphine (percent bias, −3.7% to 0.0%; %CV, 2.4% to 3.2%), norbuprenorphine (percent bias, −3.0% to −1.1%; %CV, 2.7% to 4.6%), and rosuvastatin (percent bias, −0.281% to 1.76%; %CV, 0.915% to 3.87%), 100 ng/ml for ketoconazole (percent bias, −2.75% to −0.796%; %CV, 1.83% to 3.54%), 0.2 ng/ml for esculopram (percent bias, −3.94% to 3.12%; %CV, 3.36% to 5.53%), 0.5 ng/ml for duloxetine (percent bias, −4.19 to 3.87%; %CV, 2.81% to 6.06%) and pravastatin (percent bias, −1.63% to 1.53%; %CV, 3.99% to 7.80%), 1 ng/ml for R-methadone (percent bias, 0.4% to 3.3%; %CV, 1.6% to 3.1%), S-methadone (percent bias, 1.1% to 3.2%; %CV, 2.1% to 3.2%), and omeprazole (percent bias, −0.9% to 4.4%; %CV, 4.7% to 9.7%), and 5 ng/ml for R-warfarin (percent bias, −6.74% to 0.473%; %CV, 4.17% to 5.42%) and S-warfarin (percent bias, −6.78% to 1.38%; %CV, 3.83% to 5.90%). For digoxin, urine was also collected and the excreted fraction of the drug was measured (LLOQ of 2 ng/ml; percent bias, −7.80% to −0.63%; %CV, 4.99% to 18.22%).

Pharmacokinetic analyses were performed by noncompartmental methods using Phoenix WinNonlin, version 6.0 or above (Pharsight, St. Louis, MO). The main pharmacokinetic parameters of interest were the maximum observed plasma concentration (Cmax) and the area under the plasma concentration-time curve (AUC) during a dosing interval (AUCt,δ) or from time zero to infinity (AUC∞). A single dose). Additional pharmacokinetic parameters of interest included the time to Cmax (Tmax), the 24-h concentration (C24h), and the terminal phase elimination half-life (t1/2).

Pharmacodynamic evaluations. Pharmacodynamic measurements were performed to monitor for signs of withdrawal that could have been
caused by changes in methadone and buprenorphine-naloxone exposures during coadministration with the 2D regimen. The pupil diameter and two self-administered instruments (the short opiate withdrawal scale score and the desire for drugs questionnaire) were measured before and during coadministration.

### Statistical analyses
Statistical analyses were conducted using SAS, version 9.2 (SAS Institute, Inc., Cary, NC). The effects of ombitasvir and paritaprevir-ritonavir on the interacting medications and vice versa were estimated by analysis of log-transformed $C_{\text{max}}$ and AUC values under a repeated-measures analysis framework. The geometric mean ratios (GMRs) and 90% confidence intervals (CIs) for $C_{\text{max}}$ and AUC were calculated to quantify the magnitude of drug interactions.

### RESULTS

#### Subject demographics
A total of 119 subjects, 76% of whom were male, received at least one dose of the 2D regimen and/or interacting medication in these studies. The demographics of subjects across the studies were similar: the ages of the subjects ranged from 20 to 55 years, the mean age ranged from 30.3 to 39.1 years, and the median body weight ranged from 72.5 to 80.0 kg. Across the arms receiving the 2D regimen, 60.5% of the subjects were white, 34.5% were black, 2.5% were Asian, and 2.5% were other races.

#### Pharmacokinetics
(i) Mechanism-based drug-drug interactions. The results from the studies of the mechanism-based interactions of the substrates and inhibitors of CYPs and the substrates of drug transporters on ombitasvir, paritaprevir, and ritonavir exposures are shown in Fig. 2, and the effects of ombitasvir and paritaprevir-ritonavir on the substrates and inhibitors are shown in Fig. 3. The pharmacokinetic parameters for ombitasvir, paritaprevir, and ritonavir, and the substrates and inhibitors are presented

---

**Table 1**: Study designs used for evaluating the 11 drug interactions. PK, pharmacokinetic.

| Period 1 | Period 2 |
|----------|----------|
| Day 1 | Washout | A | B | C |
| DAAs | | Ketonezol (Days 8-9) | DAAs + Ketonezol (Day 10) | Ketonezol (Days 11-13) |

N = 12. Intensive PK sampling (9-10 samples within 24 hours) was performed on Day 1/Period 1, Day 9/Period 2A, and Day 10/Period 2B. Additional samples were collected as needed to characterize terminal phase elimination half-lives.

| Period 1 | Period 2 |
|----------|----------|
| Single Dose | Washout | A* | B* | C* |
| Interacting Medication | DAAs | DAAs + Interacting Medication | DAAs |

*Days of Dosing

- Warfarin study: Days 15-28
- Omeprazole study: Days 6-10
- Digoxin study: Days 11-24
- Escitalopram study: Days 7-20
- Duloxetine study: Days 7-20

N = 12 per study. Intensive PK sampling (10-12 samples within 24 hours) was performed on Day 1/Period 1 (all studies), the last day of dosing in Period A (all studies), the first and last day of dosing in Period 2B (omeprazole study), and the only day of dosing in Period 2B (all other studies). Additional samples were collected as needed to characterize terminal phase elimination half-lives.

| Period 1 | Period 2 |
|----------|----------|
| Single Dose | Washout | 3 to 7 Days of Dosing † | 14 Days of Dosing |
| DAAs | Pravastatin or Rosuvastatin | DAAs + Pravastatin or Rosuvastatin |

† 3 days for pravastatin (Study Days 1-3); 7 days for rosuvastatin (Study Days 1-7)

N = 12 for each statin. Intensive PK sampling (10-11 samples within 24 hours) was performed on Day 1 in Period 1 and on the first and last day of dosing with the statins alone and the statins + DAAs in Period 2. Additional samples were collected as needed to characterize terminal phase elimination half-lives.

| Days 1-8 | Days 9-22 | Days 23-25 |
|----------|----------|----------|
| Methadone or Buprenorphine/Naloxone | DAAs + Methadone or Buprenorphine/Naloxone | Methadone or Buprenorphine/Naloxone |

N = 12 for methadone and 11 for buprenorphine/naloxone. Intensive PK sampling (10-13 samples within 24 hours) was performed on Days 8, 9, and 22. Additional samples were collected as needed to characterize terminal phase elimination half-lives.
in Table 2. The magnitude of each drug interaction is discussed below.

(a) CYP3A and P-gp inhibitor (ketoconazole). When ketoconazole was coadministered with the 2D regimen, the ketoconazole $C_{\text{max}}$ was not affected (10% increase), but the ketoconazole AUC increased by 105%. The mean $t_{1/2}$ of ketoconazole was almost 4-fold longer (16.0 versus 4.3 h) in the presence of ombitasvir and paritaprevir-ritonavir. Increased $C_{\text{max}}$ and AUC values were also observed for paritaprevir (72% and 116%, respectively) and ritonavir (27% and 51%, respectively). The ombitasvir $C_{\text{max}}$ was not affected (2% decrease), but the AUC increased by 26%. The mean $t_{1/2}$ of paritaprevir was more than 2-fold longer (14.4 versus 6.2 h), and the mean $t_{1/2}$ of ombitasvir increased from 24.9 to 39.5 h.

(b) CYP2C9 substrate (warfarin). Coadministration of warfarin with the 2D regimen did not affect $R$- or $S$-warfarin exposures ($\pm 15\%$ change in the $C_{\text{max}}$ and AUC values) or ombitasvir, paritaprevir, or ritonavir exposures ($\pm 15\%$ change in the $C_{\text{max}}$ and AUC values).

(c) CYP2C19 substrate (omeprazole). In the presence of the 2D regimen, the $C_{\text{max}}$ and AUC values of omeprazole were reduced by 52% and 54%, respectively. Paritaprevir, ritonavir, and ombitasvir exposures were relatively unchanged ($\pm 7\%$ change in the $C_{\text{max}}$ and AUC values) by coadministration with omeprazole.

(d) P-gp substrate (digoxin). When digoxin was coadministered with the 2D regimen, the values for digoxin $C_{\text{max}}$, AUC, and $C_{24}$ increased by 58%, 36%, and 24%, respectively. There was no change in the fraction of unchanged drug eliminated in the urine.

FIG 2 Effect of concomitant medications on the $C_{\text{max}}$ and AUC values of ombitasvir, paritaprevir, and ritonavir. The geometric mean ratios indicate the $C_{\text{max}}$ and AUC values for coadministration of the 2D regimen of ombitasvir and paritaprevir-ritonavir with the medication versus administration of the 2D regimen alone.
Ombitasvir, paritaprevir, and ritonavir exposures were not affected by coadministration with digoxin (15% change in the $C_{\text{max}}$ and AUC values).

(e) OATP1B1/B3 substrate (pravastatin). Coadministration of pravastatin with the 2D regimen increased the pravastatin $C_{\text{max}}$ and AUC values by 43% and 76%, respectively. Coadministration increased the paritaprevir $C_{\text{max}}$ and AUC values by 44% and 33% and increased the ritonavir $C_{\text{max}}$ and AUC values by 37% each, but had no effect on the ombitasvir $C_{\text{max}}$ or AUC value (6% decrease).

(f) OATP1B1/B3 and BCRP substrate (rosuvastatin). Rosuvastatin exposures increased in the presence of the 2D regimen: $C_{\text{max}}$ increased by 161% and AUC increased by 33%. The paritaprevir $C_{\text{max}}$ and AUC values by 44% and 33% and increased the ritonavir $C_{\text{max}}$ and AUC values by 37% each, but had no effect on the ombitasvir $C_{\text{max}}$ or AUC value (6% decrease).

(ii) Interactions with commonly used medications. The effects of the 2D regimen on exposures of medications commonly used in HCV-infected patients are presented in Fig. 3, and the effects of these commonly used medications on the exposures of ombitasvir, paritaprevir, and ritonavir are presented in Fig. 2. The pharmacokinetic parameters for the DAAs, ritonavir, and the commonly used medications are presented in Table 2.

(a) Addiction treatment medications (methadone and buprenorphine-naloxone). Coadministration of the 2D regimen with methadone did not affect the R- or S-methadone exposure (6% decrease in the $C_{\text{max}}$ and AUC values). Likewise, coadministration did not affect naloxone exposures (11% change in the $C_{\text{max}}$ and AUC values). In contrast, the buprenorphine $C_{\text{max}}$ and AUC values increased by 19% and 51%, respectively, and the norbuprenorphine $C_{\text{max}}$ and AUC values increased by 82% and 111%, respectively, upon coadministration. The increases in the buprenorphine and norbuprenorphine exposures did not appear to have an effect on the pharmacodynamics of these medications, as there were no significant changes in the pupil diameter, the opioid withdrawal scale score, or the desire for drug questionnaire score upon coadministration with ombitasvir and paritaprevir-ritonavir.

(b) Antidepressants (escitalopram and duloxetine). In the presence of the 2D regimen, the $C_{\text{max}}$ and AUC values of escitalopram, its metabolite S-desmethylcitalopram, and duloxetine were not affected (20% change) except for a 25% decrease in the escitalopram AUC. The exposures of ombitasvir, paritaprevir, and ritonavir were not affected by coadministration with duloxetine (10% change in the $C_{\text{max}}$ and AUC values) but were increased by 2% to 38% by coadministration with escitalopram.
| Study         | C$_{\text{max}}$ (ng/ml) Alone | C$_{\text{max}}$ (ng/ml) Coadministration | AUC (ng · h/ml) Alone | AUC (ng · h/ml) Coadministration |
|---------------|--------------------------------|-----------------------------------------|----------------------|----------------------------------|
| **Ketoconazole** |                                |                                         |                      |                                  |
| Paritaprevir  | 972 (70)                       | 1,675 (62)                              | 6,070 (61)$^b$       | 13,100 (51)$^b$                  |
| Ritonavir     | 1,460 (41)                     | 1,850 (29)                              | 9,440 (55)$^b$       | 14,300 (38)$^b$                  |
| Ombitasvir    | 113 (15)                       | 110 (16)                                | 1,700 (19)$^b$       | 2,130 (17)$^b$                   |
| Ketoconazole  | 11.1 (20)                      | 12.2 (20)                               | 86.5 (22)$^a$        | 177 (21)$^a$                     |
| **Warfarin**  |                                |                                         |                      |                                  |
| Paritaprevir  | 934 (113)                      | 1,080 (106)                             | 5,300 (113)$^d$      | 5,870 (102)$^d$                  |
| Ritonavir     | 2,030 (29)                     | 2,070 (35)                              | 11,700 (31)$^d$      | 11,700 (31)$^d$                  |
| Ombitasvir    | 124 (17)                       | 127 (18)                                | 1,210 (23)$^d$       | 1,270 (20)$^d$                   |
| R-Warfarin    | 269 (11)                       | 255 (16)                                | 19,900 (21)$^b$      | 16,700 (19)$^b$                  |
| S-Warfarin    | 272 (12)                       | 240 (14)                                | 13,000 (25)$^b$      | 11,000 (33)$^b$                  |
| **Omeprazole** |                                |                                         |                      |                                  |
| Paritaprevir  | 2,020 (76)                     | 2,060 (97)                              | 11,100 (85)$^d$      | 10,300 (101)$^d$                 |
| Ritonavir     | 2,140 (25)                     | 2,260 (29)                              | 11,700 (31)$^d$      | 11,700 (31)$^d$                  |
| Ombitasvir    | 138 (36)                       | 132 (36)                                | 1,210 (23)$^d$       | 1,270 (20)$^d$                   |
| **Digoxin**   |                                |                                         |                      |                                  |
| Paritaprevir  | 1,210 (100)                    | 1,390 (108)                             | 5,660 (95)$^d$       | 6,320 (107)$^d$                  |
| Ritonavir     | 2,170 (47)                     | 2,290 (47)                              | 12,600 (49)$^c$      | 12,800 (47)$^c$                  |
| Ombitasvir    | 148 (27)                       | 147 (26)                                | 1,430 (27)$^d$       | 1,460 (28)$^d$                   |
| **Pravastatin** |                                |                                         |                      |                                  |
| Paritaprevir  | 230 (105)                      | 153 (144)                               | 1,610 (85)$^d$       | 1,300 (119)$^d$                  |
| Ritonavir     | 706 (70)                       | 814 (55)                                | 4,420 (53)$^d$       | 5,380 (63)$^d$                   |
| Ombitasvir    | 121 (30)                       | 124 (26)                                | 1,020 (25)$^d$       | 1,010 (40)$^d$                   |
| Pravastatin   | 18.5 (36)                      | 26.3 (27)                               | 49.4 (30)$^d$        | 86.0 (25)$^d$                    |
| **Rosuvastatin** |                               |                                         |                      |                                  |
| Paritaprevir  | 296 (151)                      | 413 (141)                               | 2,010 (103)$^d$      | 2,450 (83)$^d$                   |
| Ritonavir     | 1,110 (56)                     | 1,170 (57)                              | 7,240 (59)$^d$       | 6,780 (57)$^d$                   |
| Ombitasvir    | 123 (22)                       | 110 (27)                                | 1,020 (21)$^d$       | 897 (22)$^d$                     |
| Rosuvastatin  | 2.33 (45)                      | 6.09 (64)                               | 23.0 (46)$^d$        | 30.7 (46)$^d$                    |
| **Duloxetine** |                                |                                         |                      |                                  |
| Paritaprevir  | 545 (173)                      | 583 (167)                               | 3,450 (190)$^d$      | 3,320 (175)$^d$                  |
| Ritonavir     | 925 (72)                       | 975 (59)                                | 5,640 (80)$^d$       | 6,220 (63)$^d$                   |
| Ombitasvir    | 112 (36)                       | 116 (41)                                | 1,340 (36)$^d$       | 1,400 (38)$^d$                   |
| Duloxetine    | 38 (38)                        | 32 (51)                                 | 648 (41)$^b$         | 519 (55)$^b$                     |
| **Escitalopram** |                              |                                         |                      |                                  |
| Paritaprevir  | 455 (93)                       | 540 (45)                                | 2,700 (66)$^d$       | 2,760 (41)$^d$                   |
| Ritonavir     | 1,170 (46)                     | 1,620 (29)                              | 6,780 (42)$^d$       | 8,450 (25)$^d$                   |
| Ombitasvir    | 111 (28)                       | 128 (26)                                | 1,270 (22)$^d$       | 1,310 (19)$^d$                   |
| Escitalopram  | 9.19 (28)                      | 8.86 (21)                               | 262 (32)$^b$         | 209 (35)$^b$                     |
| S-Desmethylcitalopram | 1.51 (26) | 1.77 (26) | 153 (16)$^b$ | 167 (11)$^b$ |
| **Methadone** |                                |                                         |                      |                                  |
| Paritaprevir  | ND                             | 218 (167)                               | ND                   | 1,300 (145)$^d$                  |
| Ritonavir     | ND                             | 1,460 (37)                              | ND                   | 9,970 (31)$^b$                   |
| Ombitasvir    | ND                             | 90.9 (37)                               | ND                   | 1,080 (37)$^b$                   |
| R-Methadone   | 3.60 (22)$^f$                  | 3.37 (16)$^f$                           | 60.9 (25)$^{c,e}$    | 58.9 (17)$^{c,e}$                |
| S-Methadone   | 4.76 (31)$^f$                  | 4.49 (33)$^f$                           | 71.7 (37)$^{c,e}$    | 68.6 (43)$^{c,e}$                |

(Continued on following page)
(iii) $T_{\text{max}}$ and $t_{1/2}$. The values for $T_{\text{max}}$ and $t_{1/2}$ (where calculated) for ombitasvir, paritaprevir, ritonavir, or the interacting medications were not affected in a meaningful way, except in the ketoconazole study, as described earlier.

Safety. Four subjects experienced adverse events that led to premature discontinuation from the studies. One subject in the warfarin study experienced an adverse event of rhabdomyolysis that was considered by the investigator to have a reasonable possibility of being related to the 2D regimen. This subject’s creatine phosphokinase (CPK) level was elevated at screening and continued to be elevated after the single dose of warfarin and prior to initiation of the 2D regimen. The CPK level temporarily declined upon administration of the 2D regimen but then increased significantly, which led to discontinuation of the 2D regimen. The subject was not taking any other medications. The elevation/fluctuation of CPK in this subject before 2D administration suggests that causes other than the 2D therapy may have precipitated the event. The subject was referred to a rheumatologist but did not keep the appointment and was lost to follow-up. One subject in the statin study experienced vomiting during coadministration of pravastatin and the 2D regimen. The event of vomiting resolved without intervention after the study drugs were discontinued and was considered by the investigator to have a reasonable possibility of being related to the 2D regimen. The third subject (escitalopram-duloxetine study) experienced an adverse event of lobar pneumonia and asthma, fatigue, rash, and pruritus, and skin reactions (19).

In the current studies, the changes in the DAA exposures from the 2D regimen were limited (≤51%), except for the increase in paritaprevir exposures observed upon coadministration with ketoconazole (up to 116% increase). In phase 2 studies, higher doses (200 mg, $n = 85$, or 250 mg, $n = 19$) of paritaprevir have shown acceptable safety profiles (20, 21). These doses provided exposures approximately 93% higher (200 mg) and 250% higher (250 mg) than those observed with the 150-mg paritaprevir dose administered in the current studies (22). The changes in ombitasvir exposures in the presence of the concomitant medications ranged from a 12% lower $C_{\text{max}}$ with rosuvastatin to a 26% higher AUC with ketoconazole. Ombitasvir doses of 5 mg to 200 mg have been evaluated with pegylated interferon alpha-2a plus ribavirin for 12 weeks in 23 HCV genotype 1-infected patients (23). The safety and efficacy profiles across these 5-fold lower and 8-fold higher ranges of exposures were comparable to those observed with the 25-mg dose of ombitasvir. No dose adjustment is required for ombitasvir and paritaprevir-ritonavir based on the drug interactions evaluated with the 2D regimen.

### DISCUSSION

The potential for drug-drug interactions with the 2D regimen of ombitasvir and paritaprevir-ritonavir was determined from mechanistic, in vivo evaluations using probe substrates and inhibitors and evaluations of medications likely to be coprescribed in HCV-infected patients. The evaluations were conducted with the 2-DAA combination (2D) regimen, rather than with the individual DAAs, to provide findings that would be clinically relevant. Drug-drug interactions are of particular concern in HCV-infected patients because these interactions may increase the frequency or severity of adverse events, potentially resulting in poor treatment compliance and the emergence of viral resistance. In a study of 135 HCV genotype 4-infected patients receiving the 2D regimen with or without ribavirin, the most commonly reported adverse events were asthenia, fatigue, nausea, insomnia, pruritus, and skin reactions (19).
Ribavirin is administered with the 2D regimen for HCV infection with either genotype 2 or genotype 4. Ribavirin does not share common disposition pathways with the DAAs and is not expected to contribute to the DAA drug interactions. Furthermore, the duration of dosing in the current drug-drug interaction studies ranged from 2 to 4 weeks. Given the toxicity of ribavirin, it was not deemed appropriate to give ribavirin to healthy subjects for these durations, especially because an interaction was not expected.

For the interacting medications, the clinical relevance of the magnitude of interaction was determined based on data from package inserts, regulatory documents, or literature. Dosing recommendations for medications evaluated in these studies and other medications with similar metabolic/transporter pathways were developed for HCV-infected patients (Tables 3 and 4) and are discussed below.

**Mechanism-based drug-drug interactions.** In the drug-drug interaction study with the potent CYP3A (and P-gp) inhibitor, ketoconazole, minimal to modest increases in paritaprevir, ombitasvir, and ritonavir exposures and paritaprevir and ombitasvir half-lives were observed. These increases do not necessitate dose adjustments for ombitasvir or paritaprevir-ritonavir. However, the dose of ketoconazole should be limited to 200 mg/day or less due to the 105% increase in the AUC and the 4-fold longer half-life.

Exposures of the CYP2C19 substrate, omeprazole, decreased when omeprazole was coadministered with the 2D regimen, which can be attributed to the known CYP2C19 induction by ritonavir (24–26). The reason for the variability in omeprazole exposures in the presence of the 2D regimen is not known, although omeprazole generally exhibits highly variable plasma concentrations. CYP2C19 genotyping (9 extensive metabolizers, 2 intermediate metabolizers, and no poor metabolizers) did not reveal a discernible trend in the exposure data among the subjects in the study. Other factors, such as interindividual differences in hepatic intrinsic clearance, may explain the variability (24). Although a priori dose modification is not required for omeprazole or other CYP2C9 substrates, higher doses should be considered if clinically indicated.

The study with the CYP2C9 substrate, warfarin, suggests that ombitasvir and paritaprevir-ritonavir do not induce or inhibit CYP2C9. However, routine clinical monitoring is recommended for warfarin. No dose adjustment is required for other broad-spectrum drugs that are CYP2C9 substrates (e.g., nonsteroidal anti-inflammatory drugs like ibuprofen and anti-diabetics like glimepiride and glipizide).

**In vitro** data suggest that paritaprevir and ritonavir are potential inhibitors of P-gp (13). Modest increases in digoxin exposures of 36% to 58% were observed during coadministration with the 2D regimen, suggesting that the 2D regimen inhibits P-gp in vivo. As a result, the digoxin dose should be reduced by 30% to 50% and routine therapeutic drug monitoring should be performed for digoxin during coadministration with the 2D regimen. Lower doses are recommended for other P-gp substrates when coadministered with the 2D regimen.

**In vitro** data also suggest that paritaprevir and ritonavir are BCRP inhibitors and that paritaprevir is an OATP1B1/B3 inhibitor (13). Accordingly, exposures of pravastatin (OATP1B1/B3 substrate) and rosuvastatin (OATP1B1/B3 plus BCRP substrate) showed clinically significant increases. Rosuvastatin exposures in-

---

**TABLE 3 Dosing recommendations from mechanism-based drug-drug interaction studies**

| Mechanism evaluated | Probe substrate or inhibitor | Recommendation when coadministered with the 2D regimen |
|---------------------|------------------------------|------------------------------------------------------|
| CYP3A and P-gp inhibition | Ketoconazole | Limit ketoconazole and itraconazole doses to ≤200 mg/day. Lower doses are recommended for posaconazole. |
| CYP2C9 inhibition | Warfarin | No dose adjustment is required for warfarin; routine international normalized ratio (INR) monitoring is recommended. No interaction is expected for the other CYP2C9 substrates (e.g., NSAID\(^ b\) including celecoxib and ibuprofen and anti-diabetics including glimepiride, glipizide, and tolbutamide). |
| CYP2C19 inhibition/induction and effect of acid-reducing agents | Omeprazole | No a priori dose adjustment is required; increase the dose if clinically indicated for omeprazole and other CYP2C19 substrates (e.g., lansoprazole, esomeprazole, and pantoprazole). |
| P-gp inhibition | Digoxin | Reduce the digoxin dose by 30% to 50%; routine therapeutic drug monitoring is recommended. Lower doses are recommended for other P-gp substrates (e.g., talinolol). |
| OATP1B1/B3 inhibition | Pravastatin | Reduce the pravastatin dose by half; lower doses are recommended for other OATP1B1/B3 substrates (e.g., angiotensin II receptor blockers including valsartan, olmesartan, and telmisartan and statins including pitavastatin and fluvastatin). |
| OATP1B1/B3 and BCRP inhibition | Rosuvastatin | Reduce the rosuvastatin dose by half; lower doses are recommended for other BCRP substrates (e.g., sulfasalazine). |

\(^ a\) Consult approved local labels for country-specific dosing recommendations.

\(^ b\) NSAIDs, nonsteroidal anti-inflammatory drugs.

---

**TABLE 4 Dosing recommendations based on drug-drug interactions with commonly used medications**

| Drug class | Medication | Recommendation when coadministered with the 2D regimen |
|------------|------------|------------------------------------------------------|
| Antiadditives | Methadone | No dose adjustment |
| | Buprenorphine | No dose adjustment |
| | Naloxone | No dose adjustment |
| Antidepressants | Escitalopram or citalopram | No dose adjustment for escitalopram or citalopram |
| | Duloxetine | No dose adjustment for duloxetine, paroxetine, or desipramine |

\(^ a\) Consult approved local labels for country-specific dosing recommendations.
In conclusion, a comprehensive evaluation of drug-drug interaction study results for carbamazepine, amiodipine, alprazolam, zolpidem, furosemide, oral contraceptives, and gemfibrozil can be inferred for the 2D regimen based on results from treatment arms that received the 3D regimen (11, 18, 19). During coadministration with the 2D regimen, no dose adjustment is needed for gemfibrozil (contraindicated with the 3D regimen due to an interaction with dasabuvir), zolpidem, or nortriptyline. No a priori dose adjustment is needed for alprazolam or furosemide, but clinical monitoring is recommended because of potentially modest increases in alprazolam exposures due to CYP3A inhibition by ritonavir and modest increases in furosemide exposures due to UGT-mediated inhibition of the 3D regimen by ombitasvir and paritaprevir. The amiodipine dose should be reduced by half due to increases in amiodipine exposures upon ritonavir-mediated inhibition of CYP3A. Carbamazepine and ethinyl estradiol-containing contraceptives are contraindicated with both the 2D and 3D regimens.

No dose adjustment is required for the 2D regimen when coadministered with any of the medications that are not contraindicated.

ACKNOWLEDGMENTS

We thank the subjects for their participation and the investigators and clinical sites for their help in conducting the studies. We also thank AbbVie personnel Jeffrey Arnold, Kristal Gibbons, Lillian Lee, Lisa Hernandez, Jack Clifton, Ingrid Facey, Matthew Kosloski, Matthew Dufek, Teresa Turner, David Carter, Peter Probst, Pamela Watson, Michael Duggan, Sundeep Grewal, and Natalie Hycott for their contributions to various aspects of the studies.

All authors are employees of AbbVie, Inc., and may hold AbbVie stock or stock options. Medical writing support was provided by Allison Kitten, a full-time employee of AbbVie.

FUNDING INFORMATION

This work was supported by AbbVie. AbbVie contributed to the study design, research, and interpretation of data and the writing, reviewing, and approving of the publication.

REFERENCES

1. Asselah T, Marcellin P. 2015. Optimal IFN-free therapy in treatment-naive patients with HCV genotype 1 infection. Liver Int 35(Suppl 1):S6–64. http://dx.doi.org/10.1111/liv.12745.
2. Peter J, Nelson DR. 2015. Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients. Liver Int 35(Suppl 1):65–70. http://dx.doi.org/10.1111/liv.12718.
3. DeGoei DA, Randolph JT, Liu D, Pratt J, Hutchins C, Donner P, Krueger AC, Matulenko M, Patel S, Motter CE, Nelson L, Keddy R, Tufano M, Caspi DD, Krishnan P, Mishy N, Koev G, Reisch TJ, Mondal R, pilot-Matias T, Gao Y, Beno DW, Maring CJ, Molla A, Dumas E, Campbell A, Williams L, Collins G, Wagner R, Kati WM. 2014. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem 57:2047–2057. http://dx.doi.org/10.1021/jm401398x.
4. Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoei D, Kati W, Campbell A, Williams L, Xie W, Setze C, Molla A, Collins G, Pilot-Matias T. 2015. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother 59:979–987. http://dx.doi.org/10.1128/AAC.04226-14.
5. Pilot-Matias T, Tripathi R, Cohen D, Gauthier J, Dekhtyar T, Lu L, Reich S, Irvin M, Hopkins T, Pithawallia B, Middleton T, Ng T, McDonald K, ORS, Menon R, Kempf D, Molla A, Collins C. 2015. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother 59:988–997. http://dx.doi.org/10.1128/AAC.04227-14.
6. Bernstein B, Menon RM, Klein CE, Lawal AA, Nada A, Gauthier I, Bode RM, Postecki T, Awini WM. 2009. Pharmacokinetics, safety and tolerability of the HCV protease inhibitor ABT-450 with ritonavir following multiple ascending doses in healthy adult volunteers. Glob Antiviral Res 1(Suppl 1):53.
7. Lawitz E, Sullivan G, Rodriguez-Torres M, Bennett M, Poodrad F, Kapoor M, Badri P, Campbell A, Rodrigues L, Jr, Hu Y, Pilot-Matias T, Vilchez RA. 2015. Exploratory trial of ombitasvir and ABT-450/ritonavir in HCV treatment-experienced patients. J Infect 70:197–205. http://dx.doi.org/10.1016/j.jinf.2014.09.008.
8. Chayama K, Motsumata K, Kurosaki M, Sato K, Rodrigues L, Jr, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Kumada H. 2015. Randomized trial of interferon- and ribavirin-free ombitasvir-paritaprevir/ritonavir in treatment-experienced HCV-infected patients. Hepatology 61:1523–1532. http://dx.doi.org/10.1002/hep.27705.
9. Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischers-Stempniewska K, Marcellin P, Hall C, Schnell G, Pilot-Matias T, Mobasher N, Redman R, Vilchez RA, Pol S. 2015. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 385:2502–2509. http://dx.doi.org/10.1016/S0140-6736(15)60159-3.
10. AbbVie, Inc. 2015. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) prescribing information. AbbVie, Inc., North Chicago, IL.
11. AbbVie, Ltd. 2015. Viekirax (ombitasvir/paritaprevir/ritonavir). EU summary of product characteristics. AbbVie, Ltd., Maidenhead, United Kingdom.
12. AbbVie, Ltd. 2015. Exviera (dasabuvir). EU summary of product characteristics. AbbVie, Ltd., Maidenhead, United Kingdom.

13. Badri PS, King JR, Polepally AR, McGovern BH, Dutta S, Menon RM. 2 September 2015. Dosing recommendations for concomitant medications during 3D anti-HCV therapy. Clin Pharmacokinet http://dx.doi.org/10.1007/s40262-015-0317-8.

14. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. 2012. Guidance for industry: drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. Draft guidance. Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf.

15. European Medicines Agency. 2012. Guideline on the investigation of drug interactions. CPMP/EWP/560/95/Rev 1 Corr. 2. European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf.

16. Lauffenburger JC, Mayer CL, Hawke RL, Brouwer KL, Fried MW, Farley JF. 2014. Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. Eur J Gastroenterol Hepatol 26:1073–1082. http://dx.doi.org/10.1097/MEG.0000000000000152.

17. Badri P, Dutta S, Coakley E, Cohen D, Ding B, Podsadecki T, Bernstein B, Awni W, Menon R. 2015. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant 15:1313–1322. http://dx.doi.org/10.1111/ajt.13111.

18. Menon R, Badri P, Wang T, Polepally AR, Zha J, Khatri A, Wang H, Hu B, Coakley EP, Podsadecki TJ, Awni WM, Dutta S. 2015. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir and dasabuvir. J Hepatol 63:20–29. http://dx.doi.org/10.1016/j.jhep.2015.01.026.

19. AbbVie, Inc. 2015. Technivie (ombitasvir, paritaprevir, and ritonavir tablets) prescribing information. AbbVie, Inc., North Chicago, IL.

20. Poordad F, Lawitz E, Kowdle KY, Cohen DE, Podsadecki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. 2013. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 368:45–53. http://dx.doi.org/10.1056/NEJMoa1208809.

21. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P, Foster GR, Sulkowski MS, Xie W, Pilot-Matias T, Liossis G, Larsen L, Khatri A, Podsadecki T, Bernstein B. 2014. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 370:222–232. http://dx.doi.org/10.1056/NEJMoa1306227.

22. Mensing S, Polepally A, Konig D, Khatri A, Liu W, Podsadecki T, Awni W, Menon R, Dutta S. 2014. Population pharmacokinetics of ABT-450, ombitasvir, dasabuvir, ritonavir and ribavirin in subjects with HCV genotype 1 infection. J Pharmacokinet Pharmacodyn 41:542–543.

23. Sullivan GJ, Rodrigues-Torres M, Lawitz E, Poordad F, Kapoor M, Campbell A, Setze C, Xie W, Kahlri A, Dumas E, Krishnan P, Pilot-Matias T, Williams L, Bernstein B. 2012. ABT-267 combined with pegylated interferon alpha-2a/ribavirin in genotype 1 (GT1) HCV-infected treatment-naïve subjects: 12 week antiviral and safety analysis. J Hepatol 56(Suppl 2):S480.

24. Chiba K, Shimizu K, Kato M, Nishihayashi T, Terada K, Isumo N, Sugiyama Y. 2014. Prediction of inter-individual variability in the pharmacokinetics of CYP2C19 substrates in humans. Drug Metab Pharmacokinet 29:379–386. http://dx.doi.org/10.1016/j.dmpk.2013.09.002.

25. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ, Jr, Klein CE, Rublein JC, Israel MS, Koba M. 2006. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP3A4, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 42:52–60.

26. Pfizer, Inc. 2015. Vfend (voriconazole) tablets prescribing information. Pfizer, Inc., New York, NY.

27. Knadler MP, Lobo E, Chappell J, Bergstrom R. 2011. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 50:281–294. http://dx.doi.org/10.2165/11539240-000000000-00000.